Kiora Pharmaceuticals Statistics
Share Statistics
Kiora Pharmaceuticals has 3.00M shares outstanding. The number of shares has increased by -61.37% in one year.
| Shares Outstanding | 3.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.80M |
| Failed to Deliver (FTD) Shares | 86 |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
The latest short interest is 3.61K, so 0.12% of the outstanding shares have been sold short.
| Short Interest | 3.61K |
| Short % of Shares Out | 0.12% |
| Short % of Float | 0.13% |
| Short Ratio (days to cover) | 0.27 |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is -1.62.
| PE Ratio | -0.2 |
| Forward PE | -1.62 |
| PS Ratio | 0 |
| Forward PS | 4.9 |
| PB Ratio | 0.41 |
| P/FCF Ratio | -0.26 |
| PEG Ratio | n/a |
Enterprise Valuation
Kiora Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.9, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.9 |
| Quick Ratio | 2.9 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.76 |
| Cash Flow / Debt | -203.04 |
| Interest Coverage | -1130.69 |
Financial Efficiency
Return on equity (ROE) is -2.05% and return on capital (ROIC) is -203.95%.
| Return on Equity (ROE) | -2.05% |
| Return on Assets (ROA) | -0.91% |
| Return on Capital (ROIC) | -203.95% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.04M |
| Employee Count | 12 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 90.32K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -31.68% in the last 52 weeks. The beta is -0.29, so Kiora Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -0.29 |
| 52-Week Price Change | -31.68% |
| 50-Day Moving Average | 3.48 |
| 200-Day Moving Average | 4.22 |
| Relative Strength Index (RSI) | 53.6 |
| Average Volume (20 Days) | 25.67K |
Income Statement
In the last 12 months, Kiora Pharmaceuticals had revenue of $0 and earned -$12.51M in profits. Earnings per share was $-24.25.
| Revenue | 0 |
| Gross Profit | -4.03M |
| Operating Income | -12.59M |
| Net Income | -12.51M |
| EBITDA | -12.35M |
| EBIT | - |
| Earnings Per Share (EPS) | -24.25 |
Balance Sheet
The company has $2.45M in cash and $106.89K in debt, giving a net cash position of $2.35M.
| Cash & Cash Equivalents | 2.45M |
| Total Debt | 106.89K |
| Net Cash | 2.35M |
| Retained Earnings | -146.98M |
| Total Assets | 38.51M |
| Working Capital | 28.12M |
Cash Flow
In the last 12 months, operating cash flow was -$9.56M and capital expenditures $1, giving a free cash flow of -$9.56M.
| Operating Cash Flow | -9.56M |
| Capital Expenditures | 1 |
| Free Cash Flow | -9.56M |
| FCF Per Share | -17.76 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
KPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -734.85% |
| FCF Yield | -96.51% |
Analyst Forecast
The average price target for KPRX is $10, which is 203% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 203% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 11, 2024. It was a backward split with a ratio of 1:9.
| Last Split Date | Jun 11, 2024 |
| Split Type | backward |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | -2.93 |
| Piotroski F-Score | 7 |